NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.

Active Not RecruitingPhase 2, Phase 3

Sponsor: Taiho Oncology, Inc.

Conditions: Advanced/Metastatic Cancer

Interventions: futibatinib, futibatinib, fulvestrant

Countries: United States, France, South Korea, Spain, United Kingdom

This is a nonrandomized, open-label, multicenter rollover study for patients who received futibatinib as monotherapy or as combination therapy in a Taiho-sponsored futibatinib study.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Provide written informed consent.
* Receiving futibatinib as monotherapy or as combination therapy in an antecedent futibatinib study and deriving clinical benefit with no undue risk as assessed by the investigator.
* Women of childbearing potential (WOCBP) must have a negative pregnancy test (urine or serum) within 7 days prior to receiving treatment. Both males and females of reproductive potential must agree to use effective birth control during study treatment and for a specified time after the last dose of study treatment.
* Ability to take medications orally (PO) (feeding tube is not permitted).

Exclusion Criteria:

• Has met any discontinuation criteria within the antecedent futibatinib study.

Locations (9)

San Francisco, California, United States
Marseille, France
Strasbourg, France
Seoul, South Korea
Barcelona, Spain
Madrid, Spain
London, United Kingdom
London, United Kingdom
London, United Kingdom